"Nausea" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.
Descriptor ID |
D009325
|
MeSH Number(s) |
C23.888.821.712
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Nausea".
Below are MeSH descriptors whose meaning is more specific than "Nausea".
This graph shows the total number of publications written about "Nausea" by people in this website by year, and whether "Nausea" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2004 | 0 | 1 | 1 |
2007 | 0 | 1 | 1 |
2011 | 1 | 0 | 1 |
2013 | 0 | 1 | 1 |
2015 | 0 | 1 | 1 |
2016 | 0 | 2 | 2 |
2018 | 0 | 1 | 1 |
2019 | 0 | 2 | 2 |
2020 | 1 | 1 | 2 |
2021 | 0 | 1 | 1 |
2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Nausea" by people in Profiles.
-
A Phase 1a/b Open-Label, Dose-Escalation Study of Etigilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors. Clin Cancer Res. 2022 Mar 01; 28(5):882-892.
-
Oral sulfate solution versus low-volume polyethylene glycol for bowel preparation: Meta-analysis of randomized controlled trials. Dig Endosc. 2022 May; 34(4):721-728.
-
Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia. Blood. 2021 02 11; 137(6):751-762.
-
Avoidable Acute Care Use Associated with Nausea and Vomiting Among Patients Receiving Highly Emetogenic Chemotherapy or Oxaliplatin. Oncologist. 2021 04; 26(4):325-331.
-
What the HEC? Clinician Adherence to Evidence-Based Antiemetic Prophylaxis for Highly Emetogenic Chemotherapy. J Natl Compr Canc Netw. 2020 06; 18(6):676-681.
-
First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies. Clin Cancer Res. 2020 03 01; 26(5):1025-1033.
-
Romidepsin Plus Liposomal Doxorubicin Is Safe and Effective in Patients with Relapsed or Refractory T-Cell Lymphoma: Results of a Phase I Dose-Escalation Study. Clin Cancer Res. 2020 03 01; 26(5):1000-1008.
-
Nonpain Symptom Management. Prim Care. 2019 Sep; 46(3):335-351.
-
Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer. Gynecol Oncol. 2018 10; 151(1):46-52.
-
Acute abdominal pain caused by hematometra in an adolescent female: a case report. J Med Case Rep. 2016 Dec 20; 10(1):369.